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The progression of Pneumocystis carinii pneumonia
was temporally monitored and quantified by real-time poly-
merase chain reaction of P. carinii–specific DNA in oral
swabs and lung homogenates from infected rats. DNA lev-
els correlated with the number of P. carinii organisms in the
rats’ lungs, as enumerated by microscopic methods. This
report is the first of a noninvasive, antemortem method that
can be used to monitor infection in a host over time. 
P
neumocystis pneumonia remains a leading opportunis-
tic infection associated with AIDS patients, even in the
era of highly active antiretroviral therapy (1). In develop-
ing countries, the incidence of infection has increased dra-
matically, with mortality rates ranging from 20% to 80%
(2). An important limitation in its clinical management has
been the inability to evaluate therapeutic response or to
temporally measure the organism numbers because of the
absence of an in vitro culture system. Our laboratory
recently showed that the presence of Pneumocystis
carinii–specific amplicons obtained from swabs of the oral
cavities of nonimmunocompromised adult rats (Rattus
norvegicus) was predictive of the development of P.
carinii  pneumonia after corticosteroid-induced immuno-
suppression (3). In the present study, we applied the oral
swab technique in combination with quantification of
organism-specific DNA using real-time polymerase chain
reaction (PCR) to monitor the progression of infection in
the rat model. 
The Study 
Thirty-two male Long Evans rats (140–160 g) known to
harbor  P. carinii were obtained from Room 004 at the
Cincinnati Veterinary Medical Unit (4). All rats produced
P. carinii amplicons from initial oral swab samples taken
before immunosuppression. After sampling, 8 of the 32
rats were euthanized and their lungs were removed and
processed as described below. The remaining 24 rats were
removed from the room and individually caged under bar-
rier conditions, as described previously (3), to prevent
transmission of infection that might occur between cage
mates or from the environment. Barrier conditions con-
sisted of the following: microisolator tops for each shoe-
box cage, which was then housed within a BioBubble (The
Colorado Clean Room Company, Fort Collins, CO); auto-
claved water, into which a sterile solution of cephadrine
(Velosef; E.R. Squibb and Sons, Inc., Princeton, NJ) was
injected for a final concentration of 0.200 mg/mL; auto-
claved cages, bedding, and tops; and irradiated Lab Chow
(Tekmar Irradiated Lab Chow, Harlan Industries,
Indianapolis, IN). To provoke P. carinii pneumonia, 4
mg/kg of methylprednisolone acetate (Depo Medrol; The
Upjohn Co., Kalamazoo, MI) was administered to the rats
weekly for 10 weeks. At 4 and 7 weeks, swab samples
were obtained from groups of eight rats; the rats were then
euthanized. Their lungs were removed for quantification
by microscopic enumeration of organism nuclei expressed
as log nuclei/mL (5) and real-time PCR analysis under
aseptic conditions. Six rats survived the 10 weeks of
immunosuppression and were processed in an identical
manner. 
DNA was extracted from the oral swabs (OS) and lung
homogenate (LH), as previously described (4). LH DNA
was evaluated by spectrophotometric analysis at 260 and
280 nm. RC primers directed to a region of the mitochon-
drial large subunit rRNA (mtLSU) were used for amplifi-
cation of P. carinii–specific DNA (6). 
Real-time PCR was performed and results were ana-
lyzed on the iCycler iQ Real-Time PCR Detection System
(BioRad Laboratories, Hercules, CA) under conditions of
rapid melting at 95°C, annealing for 5 s at 55°C, and col-
lection at 76°C for 10 s with 40 cycles of amplification.
Five microliters of a 1/5 dilution of OS DNA or 2.5 ng of
LH DNA were used in the reactions. Taq DNA (1.25 U)
polymerase (Promega, Madison, WI) was used in the real-
time PCR with a concentration of 2.5 mM MgCl2 in 25-µL
reactions. To monitor the accumulation of the products, 0.4
µL of 1/1,000 dilution of concentrated SYBR Green
(Molecular Probes, Eugene, OR) was included in the reac-
tions. All reactions were performed in triplicate. The
mtLSU product was cloned into the TOPO-TA PCR
cloning vector (InVitrogen, Carlsbad CA) (mtLSU-T-TA),
quantified by spectrophotometry, and used to generate a
standard curve. The cloned PCR product, ranging from
0.0005 pg to 0.5 pg per reaction, was used as a template;
the threshold cycles (CTs) of these reactions were then
plotted against the log amount of plasmid per reaction in
picograms. 
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fied by linear regression analysis of the CTs relative to the
standard curve (3). The concentration of P. carinii DNA in
the LH and OS samples, determined from the standard
curve in picograms, was converted to copies per milliliter
by multiplying by the dilution factor based on the original
concentration of DNA. The LH copies were log trans-
formed and expressed as log copies per milliliter. The
specificity of the reactions was verified by analysis of the
product-melting curves and by gel electrophoresis. All
products were of the expected size (137 bp) and produced
a single peak with a Tm of approximately 78°C. 
Microscopic enumeration of nuclei of the lung
homogenates was compared to real-time PCR lung
homogenate results by using Tukey-Kramer Multiple
Comparisons post-test to assess significance (InStat ver-
sion 3; GraphPad Software, Inc., San Diego, CA). Pre- and
postimmunosuppression OS samples were analyzed with
the Mann-Whitney test (InStat v. 3). Spearman Rank
Correlation was used to evaluate the correlation between
microscopic enumeration and the real-time PCR output
(Instat v.3). 
To ensure accurate and reproducible results, the effi-
ciency of the real-time PCR with the RC primer set was
evaluated for each type of sample used in this study:
mtLSU/T-TA, LH DNA, and OS DNA (Table 1). The
exponential amplification and efficiency of the reactions
were determined by evaluating the slope of the curve gen-
erated by plotting the log of known concentrations of tem-
plate DNA vs. their CTs (7). The RC primer set demon-
strated acceptable levels of exponential amplification and
efficiency with all three templates. 
The organism numbers in lung tissue, quantified by
microscopic enumeration, increased from log 4.69 after 4
weeks of immunosuppression to log 9.35 after 10 weeks of
immunosuppression (Figure, A.). No organisms were
detected in the lungs of the eight rats euthanized before the
study began (level of sensitivity = ~10,000 nuclei per
lung). The amount of P. carinii–specific DNA quantified
by real-time PCR in the LH samples increased substantial-
ly from 0 to 7 weeks, with similar levels after 7 and 10
weeks of immunosuppression (Figure, B). Only one of
eight rats euthanized at the initiation of the experiment
produced quantifiable copies of P. carinii–specific DNA,
with a level similar to those after 4 weeks of immunosup-
pression (data not shown). In every case, the postimmuno-
suppression OS taken from the rats at 4, 7, and 10 weeks
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Table 1. Efficiencies of the real-time PCR reactions
a 
Template  Range  r
2  Slope  Amplification  Efficiency 
mtLSU  0.5 to 0.0005 pgs/rx  0.999  -3.220  2.043  1.043 
LH  12.5 to 1.25 x 10-5 ngs/rx  0.966  -3.570  1.906  0.906 
OS  Undiluted to 1:8 dilution  0.973  -3.328  1.997  0.997 
aPCR, polymerase chain reaction; mtLSU, mitochondrial large ribosomal subunit RNA; LH, rat lung homogenate; OS, oral swab P. carinii–specific DNA; rx, reaction. 
Figure. Progression of Pneumocystis carinii pneumonia measured
by enumeration of organisms and real-time PCR of DNA extracted
from lung homogenates and oral swabs. Panel A: Log P. carinii
nuclei per mL of homogenized rat lung assessed by microscopic
enumeration of lung homogenates; 4 wk vs. 7 wk, p < 0.001; 4 wk
vs. 10 wk, p < 0.001; 7 wk vs. 10 wk, p < 0.001. Panel B: Log-
transformed copies of P. carinii-specific DNA (mtLSU) per mL of
lung homogenate; 4 wk vs. 7 wk, p < 0.001; 4 wk vs. 10 wk, p <
0.001; 7 wk vs. 10 wk, p > 0.05. Panel C: Copies of P. carinii-
specific DNA/mL in oral swabs taken between immunosuppression
(4, 7, and 10 wk preimmunosuppression) and at the time of
euthanasia (4, 7, and 10 wk postimmunosuppression); pre- and
post-4 wk, p = 0.0006; pre- and post-7 wk, p = 0.0037; pre- and
post-10 wk, p = 0.0221. The ranges in value for the preimmuno-
suppression oral swabs at 4, 7, and 10 wk were, respectively,
165–487 copies/mL; 98–816 copies/mL; and 380–1,667
copies/mL. Ranges for the postimmunosuppression copies/mL
after 4, 7, and 10 wk were 342–1,254; 517–5,256; and 637–6,279.
(Number of rats in the 4- and 7- wk postimmunosuppression group
= 8; number of rats in the 10-wk group = 6.)
A
B
Chad significantly more P. carinii–specific DNA than the
preimmunosuppression OS taken at the initiation of the
study (Figure, C). The amount of P. carinii–specific DNA
in the OS samples also increased over time (Figure, C). No
significant correlation was found between the amount of P.
carinii DNA detected in the preimmunosuppression OS
samples and the amount in the postimmunosuppression OS
samples, the lung homogenates, or nuclei number, suggest-
ing that the rats had equivalent but low levels of organisms
at the initiation of the study.
To determine the relationship between quantitation of P.
carinii by real-time PCR and by microscopic enumeration,
results were analyzed by Spearman rank correlation
(Table 2). A significant correlation was found between
both the amount of P. carinii DNA detected in the postim-
munosuppression OS samples and in the LH versus the
number of P. carinii nuclei. A significant correlation was
also detected between the real-time PCR quantitation of P.
carinii DNA in the OS and the LH. 
Conclusions
The combination of antemortem oral swab sampling
and real-time PCR amplification and quantification re-
ported here should be useful for the study of the
Pneumocystis infections in other experimental models and
provides a rationale for similar studies to be conducted in
the clinical setting. Real-time PCR previously has been
shown to be useful for quantitation of the level of infection
in the lungs of infected rats and mice, but the studies were
performed on postmortem samples or purified organisms
(8,9) P. jiroveci DNA levels from oral washes, induced
sputa, and bronchoalveolar lavage fluids from humans
have been quantified by using various real-time PCR tech-
niques (10–13) as well, but the findings were used for
diagnosis, detection, or quantification and did not obtain
samples from individual hosts over time. In our study, the
levels of P. carinii DNAin the oral cavities of the rats were
measured temporally and shown to correlate with the num-
bers of organisms in the lungs, establishing the oral swab
real-time PCR technique as a surrogate means of following
the progress of the infection. Successful application of this
method to the human infection would enhance epidemio-
logic studies, permit sensitive and rapid assessment of
therapeutic response, and allow basic biologic questions of
carriage length and potential reservoirs to be addressed.
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